Seven days, four weeks, one number: how liraglutide exposure actually accumulates

Native glucagon-like peptide-1 has a plasma half-life of roughly one and a half to two minutes. Dipeptidyl peptidase-4 cleaves it between the eighth and ninth residues almost as fast as the gut secretes it. Every marketed GLP-1 receptor agonist is, at bottom, an answer to that problem — and the answers differ enough that treating the class as pharmacokinetically uniform is the single most common error in lay coverage of it.

How you get seven days out of a two-minute peptide

Three engineering strategies account for essentially every long-acting agonist on the market. The first is substitution at the DPP-4 cleavage site: replacing the alanine at position 8 with a residue the enzyme cannot process removes the fastest route of degradation. The second is acylation with a fatty-acid chain, which promotes reversible binding to serum albumin; albumin-bound drug is protected from renal filtration and enzymatic attack, and dissociates slowly to provide a circulating depot. The third is fusion to a large carrier — an immunoglobulin Fc fragment, for instance — which raises the hydrodynamic radius above the glomerular filtration threshold.

Semaglutide uses the first two, with a C18 diacid linked through a spacer. Liraglutide uses a shorter C16 chain and achieves roughly thirteen hours rather than seven days, which is a useful demonstration of how much the chain contributes. Dulaglutide takes the fusion route. The strategies are not interchangeable and they produce different distribution and clearance behaviour, not merely different durations.¹

The accumulation arithmetic, worked

For a drug given at a fixed interval, the accumulation ratio at steady state is approximately 1 / (1 − e^−kτ), where τ is the dosing interval and k is the elimination rate constant, itself 0.693 divided by the half-life. For a once-weekly drug with a seven-day half-life, τ and the half-life are equal, e^−kτ is 0.5, and the accumulation ratio is 2. In plain terms: at an unchanged weekly dose, average concentration at steady state is roughly twice what it is after the first injection.

Time to steady state depends only on the half-life, not on the dose or the interval: about 94% of steady state after four half-lives, 97% after five. For a seven-day half-life that is four to five weeks. This is why a fixed four-week escalation step exists at all — it is approximately the time required for the previous dose to stop increasing — and why escalating faster than that means escalating onto a still-rising exposure curve.

These are approximations that assume linear kinetics and complete absorption. Both assumptions are reasonable for this class and neither is exact.

Receptor occupancy does not predict a clinical response. A mechanistic account that explains a result after the fact is a hypothesis about why it happened, and treating it as evidence that the result will generalise is the commonest error in writing about this class.

A missed dose, modelled

Because exposure declines with a seven-day half-life, a single missed weekly dose leaves roughly half the accumulated concentration in circulation at the point the next dose would have been due, and roughly a quarter a week after that. That is why product labelling for once-weekly agonists generally permits taking a missed dose within a defined window and otherwise skipping it, and why a single omission rarely produces a dramatic change.

An interruption of four weeks or more is a different situation. By then concentrations have fallen to a small fraction of steady state, tolerability has substantially reset, and resuming at the previous dose means presenting the receptor with an exposure step it has not seen for a month. The clinical convention — resume lower and re-escalate — follows directly from the pharmacokinetics rather than from caution alone.²

Injection timing: what the kinetics permit

At steady state on a seven-day half-life the peak-to-trough variation across the dosing interval is modest — on the order of tens of per cent rather than folds. Moving the injection by twelve hours, or from one day of the week to another, does not meaningfully change total exposure. It does change when the highest concentrations occur relative to a person’s week.

Time to maximum concentration after subcutaneous injection is on the order of one to three days for the long-acting agonists, so an injection on Friday evening produces its concentration peak somewhere in the weekend. Whether that is desirable is a question about a person’s schedule, not about pharmacology. What the pharmacology does say is that consistency of interval matters more than consistency of hour, because the interval is what determines the accumulation ratio.

Delayed gastric emptying is the mechanism, not the complication

Slowed gastric emptying is frequently described as a side effect. It is more accurately described as a mechanism that becomes an adverse effect at sufficient magnitude. Delayed emptying blunts the post-prandial glucose excursion, which is part of the glycaemic benefit, and it produces early satiety, which is part of the weight effect. Beyond a threshold it produces nausea, vomiting, reflux and the sensation of food sitting undigested.

Two properties of the effect matter clinically. It is dose-dependent, and it exhibits partial tachyphylaxis: the magnitude of delay attenuates over weeks of continued exposure at a fixed dose, which is the physiological basis for the observation that tolerability improves if a dose is held rather than escalated. The residual delay at steady state is real and is the reason pre-procedural fasting guidance for this class exists at all.³

Species matters. A receptor-level finding established in rodent tissue does not transfer cleanly, and several mechanistic claims still in circulation rest on preparations that were never human. The preparation is part of the result.

Two things follow practically from the pharmacology above, and only two. Consistency of dosing interval matters more than consistency of hour. And an interruption long enough to clear the drug is an interruption long enough to reset tolerability, which means resumption is a fresh escalation and not a continuation. Everything else in this piece is background.